PL1 Presidential Plenary: Technology and Delivery Breakthroughs in Diabetes

Program: Plenary
Translational Session
Friday, April 1, 2016: 8:00 AM-9:30 AM
Hall B2 (BCEC)

From engineering insulin to engineering cells:  Two roads from two Nobel prizes look forward to hopeful cures for diabetes

8:00 AM
Lisa H Fish, MD, Hennepin County Medical Ctr, Edina, MN
Nothing to Disclose: LHF
8:40 AM
Douglas A Melton, Professor, Dept of Stem Cell and Regener Biology, Harvard University, HHMI, Cambridge, MA
Disclosures:
DAM: Scientific Board Member, Semma Therapeutics.
9:05 AM
Edward R Damiano, PhD, Biomedical Engineering, Boston University, Boston, MA
Nothing to Disclose: ERD
See more of: Plenary

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire